Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4840) 4840
Publication (314) 314
Newspaper Article (143) 143
Newsletter (53) 53
Government Document (32) 32
Book Review (30) 30
Report (23) 23
Book / eBook (22) 22
Magazine Article (21) 21
Book Chapter (15) 15
Trade Publication Article (14) 14
Web Resource (12) 12
Dissertation (9) 9
Conference Proceeding (5) 5
Data Set (3) 3
Reference (3) 3
Paper (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (2920) 2920
male (2259) 2259
humans (1872) 1872
index medicus (1850) 1850
rats (1523) 1523
female (1368) 1368
biphenyl compounds - pharmacology (1355) 1355
pharmacology & pharmacy (1048) 1048
biphenyl compounds - administration & dosage (908) 908
mice (793) 793
toxicology (757) 757
polychlorinated biphenyls (747) 747
environmental sciences (722) 722
dose-response relationship, drug (655) 655
biphenyl compounds - therapeutic use (617) 617
tetrazoles - pharmacology (533) 533
polychlorinated-biphenyls (532) 532
adult (523) 523
rats, sprague-dawley (512) 512
blood pressure - drug effects (501) 501
losartan (488) 488
research (481) 481
middle aged (465) 465
angiotensin receptor antagonists (459) 459
polychlorinated biphenyls--pcb (458) 458
tetrazoles - administration & dosage (429) 429
administration, oral (415) 415
biphenyl compounds - chemistry (371) 371
imidazoles - pharmacology (363) 363
analysis (358) 358
public, environmental & occupational health (347) 347
hypertension - drug therapy (344) 344
rats, wistar (343) 343
aged (327) 327
tetrazoles - therapeutic use (324) 324
antioxidants - pharmacology (318) 318
health aspects (318) 318
biphenyl compounds (315) 315
time factors (308) 308
hypertension (293) 293
chemistry, medicinal (287) 287
oxidative stress (279) 279
picrates - chemistry (272) 272
antihypertensive agents - administration & dosage (269) 269
plant extracts - pharmacology (266) 266
research article (258) 258
antioxidants (256) 256
pcb (254) 254
polychlorinated biphenyls - toxicity (252) 252
biphenyl compounds - pharmacokinetics (249) 249
antihypertensive agents - pharmacology (246) 246
exposure (245) 245
pregnancy (245) 245
pesticides (243) 243
liver - drug effects (238) 238
apoptosis (237) 237
irbesartan (237) 237
antihypertensive agents - therapeutic use (236) 236
biphenyl compounds - metabolism (236) 236
toxicity (235) 235
biochemistry & molecular biology (234) 234
pcbs (225) 225
biphenyl compounds - adverse effects (222) 222
in-vitro (222) 222
risk assessment (217) 217
medicine (216) 216
persistent organic pollutants (215) 215
liver (213) 213
polychlorinated biphenyls - analysis (210) 210
disease models, animal (207) 207
inhibition (207) 207
physiological aspects (206) 206
studies (205) 205
neurosciences (204) 204
cancer (203) 203
fish (201) 201
liver - metabolism (200) 200
rat (199) 199
rodents (199) 199
peripheral vascular disease (194) 194
expression (191) 191
treatment outcome (190) 190
polybrominated diphenyl ethers (189) 189
cell line, tumor (188) 188
double-blind method (186) 186
phytotherapy (186) 186
angiotensin ii - antagonists & inhibitors (185) 185
environmental monitoring (184) 184
angiotensin ii (181) 181
metabolism (181) 181
drug therapy, combination (179) 179
free radical scavengers - pharmacology (179) 179
apoptosis - drug effects (178) 178
article (178) 178
antioxidant activity (172) 172
physiology (172) 172
angiotensin (171) 171
multidisciplinary sciences (171) 171
angiotensin ii - pharmacology (170) 170
dioxins (170) 170
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (8) 8
Engineering & Comp. Sci. - Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
Online Resources - Online (2) 2
Engineering & Comp. Sci. - May be requested in 6-10 wks (1) 1
Gerstein Science - Not Returned (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5060) 5060
Chinese (28) 28
German (22) 22
Japanese (22) 22
Russian (15) 15
French (10) 10
Italian (10) 10
Spanish (6) 6
Polish (5) 5
Ukrainian (3) 3
Danish (2) 2
Hungarian (2) 2
Lithuanian (1) 1
Norwegian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia
by Cervantes-Gomez, Fabiola and Lamothe, Betty and Woyach, Jennifer A and Wierda, William G and Keating, Michael J and Balakrishnan, Kumudha and Gandhi, Varsha
Clinical Cancer Research, ISSN 1078-0432, 08/2015, Volume 21, Issue 16, pp. 3705 - 3715
Purpose: Bruton's tyrosine kinase (BTK) is a critical enzyme in the B-cell receptor pathway and is inhibited by ibrutinib due to covalent binding to the kinase... 
B-CELL RECEPTOR | TUMOR PROLIFERATION | BRUTONS TYROSINE KINASE | CLL | ONCOLOGY | BCL-2 INHIBITOR | INITIAL THERAPY | IN-VIVO | PCI-32765 | KINASE INHIBITOR IBRUTINIB | SINGLE-ARM | Piperazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Apoptosis - drug effects | Humans | Neoplastic Cells, Circulating - metabolism | Male | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Purines - administration & dosage | Bendamustine Hydrochloride - administration & dosage | Protein-Tyrosine Kinases - genetics | Female | bcl-X Protein - biosynthesis | Protein-Tyrosine Kinases - biosynthesis | B-Cell Activating Factor - biosynthesis | Neoplastic Cells, Circulating - drug effects | Pyrimidines - administration & dosage | Gene Expression Regulation, Leukemic - drug effects | Nitrophenols - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Proto-Oncogene Proteins c-bcl-2 - biosynthesis | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Pyrazoles - administration & dosage | B-Cell Activating Factor - genetics | Biphenyl Compounds - administration & dosage | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Isoquinolines - administration & dosage | Proto-Oncogene Proteins c-bcl-2 - genetics | Sulfonamides - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors
by Rodon, Jordi and Tawbi, Hussein A and Thomas, Anne L and Stoller, Ronald G and Turtschi, Christian P and Baselga, Jose and Sarantopoulos, John and Mahalingam, Devalingam and Shou, Yaping and Moles, Melissa A and Yang, Lin and Granvil, Camille and Hurh, Eunju and Rose, Kristine L and Amakye, Dereck D and Dummer, Reinhard and Mita, Alain C
Clinical Cancer Research, ISSN 1078-0432, 04/2014, Volume 20, Issue 7, pp. 1900 - 1909
Purpose: This phase I trial was undertaken to determine the maximum tolerated dose (MTD), doselimiting toxicities (DLT), safety, tolerability,... 
CRITERIA | TRIALS | HEDGEHOG PATHWAY | VISMODEGIB | ONCOLOGY | SAFETY | CANCER | MEDULLOBLASTOMA | Carcinoma, Basal Cell - genetics | Humans | Middle Aged | Biphenyl Compounds - adverse effects | Pyridines - pharmacokinetics | Male | Pyridines - adverse effects | Medulloblastoma - pathology | Smoothened Receptor | Aged, 80 and over | Adult | Female | Gene Expression Regulation, Neoplastic - drug effects | Medulloblastoma - genetics | Biphenyl Compounds - pharmacokinetics | Pyridines - administration & dosage | Signal Transduction | Administration, Oral | Transcription Factors - biosynthesis | Carcinoma, Basal Cell - pathology | Maximum Tolerated Dose | Biphenyl Compounds - administration & dosage | Receptors, G-Protein-Coupled - antagonists & inhibitors | Carcinoma, Basal Cell - drug therapy | Aged | Receptors, G-Protein-Coupled - genetics | Zinc Finger Protein GLI1 | Medulloblastoma - drug therapy | Neoplasm Staging | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo-Controlled Phase I Studies
by Stoch, SA and Zajic, S and Stone, J and Miller, DL and Van Dyck, K and Gutierrez, MJ and De Decker, M and Liu, L and Liu, Q and Scott, BB and Panebianco, D and Jin, B and Duong, LT and Gottesdiener, K and Wagner, JA
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 08/2009, Volume 86, Issue 2, pp. 175 - 182
Inhibition of cathepsin K (CatK) is a potential new treatment for osteoporosis. In two double‐blind, randomized, placebo‐controlled phase I studies,... 
MINERAL DENSITY | TURNOVER | BIOCHEMICAL MARKERS | ROLES | PHARMACOLOGY & PHARMACY | MICE | PROTEINASES | MODEL | ALENDRONATE TREATMENT | OSTEOPOROSIS | Biphenyl Compounds - pharmacokinetics | Cathepsin K | Bone Resorption - blood | Double-Blind Method | Drug Administration Schedule | Peptides | Administration, Oral | Humans | Middle Aged | Bone Resorption - drug therapy | Biphenyl Compounds - adverse effects | Collagen Type I | Treatment Outcome | Procollagen - blood | Biomarkers - blood | Biphenyl Compounds - therapeutic use | Osteoporosis, Postmenopausal - drug therapy | Biphenyl Compounds - pharmacology | Biphenyl Compounds - administration & dosage | Peptide Fragments - blood | Female | Aged | Cathepsins - antagonists & inhibitors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Short‐term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes
by Kelly, R. P and Garhyan, P and Raddad, E and Fu, H and Lim, C. N and Prince, M. J and Pinaire, J. A and Loh, M. T and Deeg, M. A
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 04/2015, Volume 17, Issue 4, pp. 414 - 422
Aim: To describe the clinical effects of single and multiple doses of a potent, selective, orally administered, small-molecule antagonist of the human glucagon... 
pharmacokinetics | diabetes care | glucagon antagonist | pharmacology | Pharmacology | Glucagon antagonist | Pharmacokinetics | Diabetes care | HYPERGLUCAGONEMIA | MELLITUS | KNOCKOUT MICE | INSULIN | OBESITY | GLUCONEOGENESIS | ALPHA CELL HYPERPLASIA | ENDOCRINOLOGY & METABOLISM | POSTPRANDIAL HYPERGLYCEMIA | PLASMA-GLUCOSE | Glycated Hemoglobin A - analysis | Single-Blind Method | Hypoglycemia - epidemiology | Receptors, Glucagon - antagonists & inhibitors | Humans | Middle Aged | Half-Life | Male | Risk | Diabetes Mellitus, Type 2 - metabolism | Biphenyl Compounds - therapeutic use | Glucagon - blood | Glucagon - agonists | Dose-Response Relationship, Drug | Hypoglycemia - prevention & control | Hypoglycemic Agents - blood | Hypoglycemic Agents - administration & dosage | Adult | Female | Biphenyl Compounds - blood | Hypoglycemia - chemically induced | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Biphenyl Compounds - pharmacokinetics | Hypoglycemic Agents - pharmacokinetics | Molecular Targeted Therapy - adverse effects | Double-Blind Method | Cross-Over Studies | Diabetes Mellitus, Type 2 - blood | Biphenyl Compounds - administration & dosage | Aged | Glucagon - secretion | Diabetes Mellitus, Type 2 - drug therapy | Cohort Studies | Type 2 diabetes | Glucagon | Blood sugar | Low density lipoproteins | Fasting | Diabetes | Glucose
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text A Multicenter, Double-blind, Randomized, Placebo-controlled Trial of the β3-Adrenoceptor Agonist Solabegron for Overactive Bladder
by Ohlstein, Eliot H and von Keitz, Alexander and Michel, Martin C
European Urology, ISSN 0302-2838, 2012, Volume 62, Issue 5, pp. 834 - 840
Abstract Background β-Adrenoceptor agonists are effective in animal models of bladder dysfunction, and the human bladder primarily expresses the β3 receptor... 
Urology | Urinary incontinence | Overactive bladder | β3-adrenoceptor | Solabegron | Benzoates - adverse effects | Benzoates - therapeutic use | Humans | Middle Aged | Biphenyl Compounds - adverse effects | Urodynamics - drug effects | Adrenergic beta-3 Receptor Agonists - adverse effects | Biphenyl Compounds - therapeutic use | Young Adult | Urinary Bladder, Overactive - drug therapy | Time Factors | Urinary Bladder, Overactive - physiopathology | Urination - drug effects | Adult | Female | Aniline Compounds - administration & dosage | Republic of Korea | Adrenergic beta-3 Receptor Agonists - administration & dosage | Argentina | Urinary Incontinence - physiopathology | Double-Blind Method | Drug Administration Schedule | Europe | Linear Models | Treatment Outcome | Benzoates - administration & dosage | Urinary Incontinence - drug therapy | New Zealand | Adrenergic beta-3 Receptor Agonists - therapeutic use | Biphenyl Compounds - administration & dosage | Taiwan | Urinary Bladder - physiopathology | South Africa | Urinary Bladder - drug effects | Aged | Aniline Compounds - therapeutic use | Aniline Compounds - adverse effects | Australia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Odanacatib in the treatment of postmenopausal women with low bone mineral density: Five years of continued therapy in a phase 2 study
by Langdahl, Bente and Binkley, Neil and Bone, Henry and Gilchrist, Nigel and Resch, Heinrich and Rodriguez Portales, Jose and Denker, Andrew and Lombardi, Antonio and Le Bailly De Tilleghem, Celine and DaSilva, Carolyn and Rosenberg, Elizabeth and Leung, Albert
Journal of Bone and Mineral Research, ISSN 0884-0431, 11/2012, Volume 27, Issue 11, pp. 2251 - 2258
Odanacatib (ODN) is a selective inhibitor of the collagenase cathepsin K that is highly expressed by osteoclasts. In this 2‐year, phase 2, dose‐ranging trial,... 
BMD | CATHEPSIN K | ODANACATIB | BONE TURNOVER | OSTEOPOROSIS | EFFICACY | DENOSUMAB | MONTHLY ORAL IBANDRONATE | ALENDRONATE | TRIAL | MORPHEA | ENDOCRINOLOGY & METABOLISM | BALICATIB | CATHEPSIN-K INHIBITOR | FRACTURES | Biomarkers - metabolism | Postmenopause - drug effects | Bone Density Conservation Agents - adverse effects | Humans | Middle Aged | Biphenyl Compounds - adverse effects | Bone Density Conservation Agents - administration & dosage | Bone Density Conservation Agents - pharmacology | Bone and Bones - drug effects | Bone Density - drug effects | Biphenyl Compounds - pharmacology | Bone and Bones - metabolism | Biphenyl Compounds - administration & dosage | Aged, 80 and over | Female | Aged | Osteoporosis | Medical colleges | Care and treatment | Phosphatases | Vitamin D | Collagen | Cathepsins | Bones | Calcifediol | Postmenopausal women | Alfacalcidol | Density | Creatinine | Alkaline phosphatase | Radius | Vitamin D3 | Collagen (type I) | Cathepsin K | Calcium | Spine (lumbar) | Oligonucleotides | procollagen | Collagenase | Bone turnover | Hip | Post-menopause | Bone resorption | Osteoclasts | Bone mineral density | Osteogenesis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma
by Dummer, Reinhard, MD and Guminski, Alexander, MD, PhD and Gutzmer, Ralf, MD and Dirix, Luc, MD and Lewis, Karl D., MD and Combemale, Patrick, MD and Herd, Robert M., MD and Kaatz, Martin, MD and Loquai, Carmen, MD and Stratigos, Alexander J., MD and Schulze, Hans-Joachim, MD and Plummer, Ruth, MD and Gogov, Sven, MD and Pallaud, Celine, PhD and Yi, Tingting, PhD and Mone, Manisha, PhD and Chang, Anne Lynn S., MD and Cornélis, Frank, MD and Kudchadkar, Ragini, MD and Trefzer, Uwe, MD and Lear, John T., MD and Sellami, Dalila, MD and Migden, Michael R., MD
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2016, Volume 75, Issue 1, pp. 113 - 125.e5
Background The hedgehog pathway inhibitor sonidegib demonstrated meaningful tumor shrinkage in more than 90% of patients with locally advanced basal cell... 
Dermatology | Basal Cell Carcinoma Outcomes with LDE225 Treatment study | hedgehog pathway inhibitor | sonidegib | locally advanced basal cell carcinoma | metastatic basal cell carcinoma | advanced basal cell carcinoma | Locally advanced basal cell carcinoma | Advanced basal cell carcinoma | Metastatic basal cell carcinoma | Sonidegib | Hedgehog pathway inhibitor | HEDGEHOG PATHWAY | MULTICENTER | VISMODEGIB | MANAGEMENT | EFFICACY | GUIDELINES | OPEN-LABEL | DERMATOLOGY | DOSE-ESCALATION | UPDATE | INHIBITOR | Skin Neoplasms - drug therapy | Humans | Middle Aged | Carcinoma, Basal Cell - secondary | Biphenyl Compounds - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Biphenyl Compounds - therapeutic use | Young Adult | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Smoothened Receptor - antagonists & inhibitors | Pyridines - therapeutic use | Skin Neoplasms - pathology | Pyridines - administration & dosage | Double-Blind Method | Survival Rate | Disease Progression | Biphenyl Compounds - administration & dosage | Carcinoma, Basal Cell - drug therapy | Aged | Medical research | Care and treatment | Basal cell carcinoma | Analysis | Patient outcomes | Corn | Medicine, Experimental | Skin | Metastasis | Drug therapy | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition
by Tamaki, Hiroki and Harashima, Nanae and Hiraki, Miho and Arichi, Naoko and Nishimura, Nobuhiro and Shiina, Hiroaki and Naora, Kohji and Harada, Mamoru
Oncotarget, ISSN 1949-2553, 2014, Volume 5, Issue 22, pp. 11399 - 11412
Docetaxel (DTX) is a useful chemotherapeutic drug for the treatment of hormone-refractory prostate cancer. However, emergence of DTX resistance has been a... 
Bcl-2 | Bcl-xL | Prostate cancer | Docetaxel | Apoptosis | Piperazines - administration & dosage | Prostatic Neoplasms - metabolism | Caspase Inhibitors - pharmacology | Caspase 9 - metabolism | Taxoids - pharmacology | Apoptosis - drug effects | Humans | Male | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Proto-Oncogene Proteins c-bcl-2 - metabolism | Prostatic Neoplasms - genetics | Transfection | Biphenyl Compounds - pharmacology | Nitrophenols - pharmacology | Aniline Compounds - administration & dosage | Prostatic Neoplasms - drug therapy | Caspase Inhibitors - administration & dosage | Prostatic Neoplasms - pathology | Aniline Compounds - pharmacology | Nitrophenols - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Sulfonamides - pharmacology | Piperazines - pharmacology | Drug Synergism | Xenograft Model Antitumor Assays | Taxoids - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Animals | Mice, Nude | Biphenyl Compounds - administration & dosage | Cell Line, Tumor | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Mice | Mice, Inbred BALB C | Sulfonamides - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: Performance and mechanism
by Gao, Fang and Gao, Zhiwei and Zhang, Zhiwen and Bu, Huihui and Huang, Yan and Shen, Jianan and Zhao, Chunjie and Li, Yaping
Journal of Controlled Release, ISSN 0168-3659, 2011, Volume 149, Issue 2, pp. 168 - 174
Candesartan cilexetil (CC), an inactive prodrug of candesartan, was rapidly hydrolyzed into active candesartan during absorption in the gastrointestinal (GI)... 
Oral absorption | Candesartan cilexetil | Candesartan | Nanoemulsion | LIPOPHILIC DRUGS | FORMULATION | CHEMISTRY, MULTIDISCIPLINARY | BIOAVAILABILITY | DELIVERY | SOLID LIPID NANOPARTICLES | INTESTINAL LYMPHATIC TRANSPORT | INTERNALIZATION | SPONTANEOUS EMULSIFICATION | PHARMACOLOGY & PHARMACY | FLOW BLOCKING APPROACH | CELL-LINE | Prodrugs - administration & dosage | Emulsions | Humans | Ileum - metabolism | Biological Availability | Male | Chromatography, High Pressure Liquid | Drug Carriers - chemistry | Intestinal Absorption | Jejunum - metabolism | Tetrazoles - blood | Tandem Mass Spectrometry | Benzimidazoles - administration & dosage | Biological Transport | Tetrazoles - administration & dosage | Surface Properties | Duodenum - metabolism | Biphenyl Compounds - blood | Benzimidazoles - blood | Caco-2 Cells | Microscopy, Electron, Transmission | Biphenyl Compounds - pharmacokinetics | Endocytosis - drug effects | Solubility | Benzimidazoles - pharmacokinetics | Rats | Rats, Sprague-Dawley | Mouth Mucosa - metabolism | Animals | Prodrugs - pharmacokinetics | Biphenyl Compounds - administration & dosage | Nanostructures - chemistry | Tetrazoles - pharmacokinetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
by Migden, Michael R, Dr and Guminski, Alexander, PhD and Gutzmer, Ralf, Prof and Dirix, Luc, MD and Lewis, Karl D, MD and Combemale, Patrick, MD and Herd, Robert M, MD and Kudchadkar, Ragini, MD and Trefzer, Uwe, Prof and Gogov, Sven, MD and Pallaud, Celine, PhD and Yi, Tingting, PhD and Mone, Manisha, PhD and Kaatz, Martin, MD and Loquai, Carmen, MD and Stratigos, Alexander J, Prof and Schulze, Hans-Joachim, MD and Plummer, Ruth, Prof and Chang, Anne Lynn S, MD and Cornélis, Frank, MD and Lear, John T, MD and Sellami, Dalila, MD and Dummer, Reinhard, Prof
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 6, pp. 716 - 728
Summary Background Patients with advanced basal cell carcinoma have limited treatment options. Hedgehog pathway signalling is aberrantly activated in around... 
Hematology, Oncology and Palliative Medicine | VISMODEGIB | SOLID TUMORS | ONCOLOGY | RESISTANCE | OPEN-LABEL | QUALITY-OF-LIFE | EUROPEAN-ORGANIZATION | MUTATIONS | HEDGEHOG-PATHWAY | Neoplasm Recurrence, Local - radiotherapy | Skin Neoplasms - drug therapy | Skin Neoplasms - radiotherapy | Humans | Middle Aged | Biphenyl Compounds - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | Neoplasm Recurrence, Local - surgery | Neoplasm Recurrence, Local - pathology | Neoplasm Metastasis | Pyridines - adverse effects | Aged, 80 and over | Adult | Female | Skin Neoplasms - surgery | Skin Neoplasms - pathology | Carcinoma, Basal Cell - radiotherapy | Pyridines - administration & dosage | Double-Blind Method | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Basal Cell - pathology | Disease-Free Survival | Carcinoma, Basal Cell - surgery | Biphenyl Compounds - administration & dosage | Carcinoma, Basal Cell - drug therapy | Aged | Medical colleges | Care and treatment | Basal cell carcinoma | Surgical clinics | Clinical trials | Skin | Metastasis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review
by Chow, Clara K, Prof and Thakkar, Jay, MBBS and Bennett, Alex, MPhil and Hillis, Graham, Prof and Burke, Michael, PhD and Usherwood, Tim, Prof and Vo, Kha, BSc and Rogers, Kris, PhD and Atkins, Emily, PhD and Webster, Ruth, PhD and Chou, Michael, MBBS and Dehbi, Hakim-Moulay, MRes and Salam, Abdul, PhD and Patel, Anushka, Prof and Neal, Bruce, Prof and Peiris, David, PhD and Krum, Henry, Prof and Chalmers, John, Prof and Nelson, Mark, Prof and Reid, Christopher M, Prof and Woodward, Mark, Prof and Hilmer, Sarah, Prof and Thom, Simon, Prof and Rodgers, Anthony, Prof
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10073, pp. 1035 - 1042
Summary Background Globally, most patients with hypertension are treated with monotherapy, and control rates are poor because monotherapy only reduces blood... 
Internal Medicine | USUAL CARE | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | MANAGEMENT | CARDIOVASCULAR-DISEASE | BLOOD-PRESSURE CONTROL | RISK | RENAL-DISEASE | NEPHROPATHY | LOWERING DRUGS | PROGRESSION | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Biphenyl Compounds - adverse effects | Hypertension - drug therapy | Male | Review Literature as Topic | Tetrazoles - administration & dosage | Female | Blood Pressure - drug effects | Atenolol - administration & dosage | Amlodipine - administration & dosage | Hydrochlorothiazide - adverse effects | Double-Blind Method | Administration, Oral | Amlodipine - adverse effects | Treatment Outcome | Hydrochlorothiazide - administration & dosage | Antihypertensive Agents - adverse effects | Cross-Over Studies | Medication Adherence | Irbesartan | Biphenyl Compounds - administration & dosage | Tetrazoles - adverse effects | Drug Combinations | Medicine, Preventive | Preventive health services | Hypertension | Studies | Clinical trials | Blood pressure | Drug dosages
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Odanacatib, a Cathepsin-K Inhibitor for Osteoporosis: A Two-Year Study in Postmenopausal Women With Low Bone Density
by Bone, Henry G and McClung, Michael R and Roux, Christian and Recker, Robert R and Eisman, John A and Verbruggen, Nadia and Hustad, Carolyn M and DaSilva, Carolyn and Santora, Arthur C and Ince, B. Avery
Journal of Bone and Mineral Research, ISSN 0884-0431, 05/2010, Volume 25, Issue 5, pp. 937 - 947
Cathepsin K, a cysteine protease expressed in osteoclasts, degrades type 1 collagen. Odanacatib selectively and reversibly inhibited cathepsin K and rapidly... 
clinical trial | bone mineral density | phase 2B | postmenopausal women | odanacatib | osteoporosis | cathepsin K | Bone Mineral Density | Osteoporosis | Cathepsin K | Clinical Trial | Postmenopausal Women | Phase 2B | Odanacatib | CLINICAL TRIAL | TARGET | RESORPTION | TURNOVER | COLLAGEN | CATHEPSIN K | OSTEOPOROSIS | PHASE 2B | ALENDRONATE | MINERAL DENSITY | BONE MINERAL DENSITY | ODANACATIB | IN-VIVO | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | BALICATIB | RISEDRONATE | POSTMENOPAUSAL WOMEN | Bone and Bones - pathology | Bone Density | Lumbar Vertebrae - metabolism | Double-Blind Method | Humans | Middle Aged | Biphenyl Compounds - adverse effects | Bone Density Conservation Agents - therapeutic use | Osteoporosis, Postmenopausal - pathology | Biphenyl Compounds - therapeutic use | Osteoporosis, Postmenopausal - drug therapy | Bone and Bones - metabolism | Biphenyl Compounds - administration & dosage | Aged, 80 and over | Female | Aged | Cathepsin K - antagonists & inhibitors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats
by Zhang, Zhiwen, PhD and Gao, Fang, MPharm and Bu, Huihui, MPharm and Xiao, Jisheng, MPharm and Li, Yaping, PhD
Nanomedicine: Nanotechnology, Biology, and Medicine, ISSN 1549-9634, 2012, Volume 8, Issue 5, pp. 740 - 747
Abstract Candesartan cilexetil (CC) is widely used for the treatment of hypertension and heart failure, but it shows very poor aqueous solubility and very low... 
Internal Medicine | Oral bioavailability | Candesartan | Lymphatic transport | Solid lipid nanoparticles | MEDICINE, RESEARCH & EXPERIMENTAL | EFFICACY | HEART-FAILURE | LIPOPHILIC DRUGS | NANOSCIENCE & NANOTECHNOLOGY | DELIVERY | INTESTINAL LYMPHATIC TRANSPORT | PHARMACOKINETICS | FORMULATIONS | FLOW BLOCKING APPROACH | HYPERTENSION | CACO-2 CELLS | Nanoparticles - chemistry | Humans | Intestinal Absorption - drug effects | Antihypertensive Agents - administration & dosage | Biological Availability | Male | Benzimidazoles - chemistry | Lipids - chemistry | Benzimidazoles - administration & dosage | Tetrazoles - chemistry | Tetrazoles - administration & dosage | Biphenyl Compounds - chemistry | Caco-2 Cells | Biphenyl Compounds - pharmacokinetics | Administration, Oral | Benzimidazoles - pharmacokinetics | Rats | Antihypertensive Agents - pharmacokinetics | Rats, Sprague-Dawley | Gastrointestinal Tract - metabolism | Antihypertensive Agents - chemistry | Animals | Biphenyl Compounds - administration & dosage | Nanoparticles - administration & dosage | Tetrazoles - pharmacokinetics | Hypertension | Nanoparticles
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights